Tag: grants

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

SHREWSBURY, United Kingdom, July 06, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the decentralized AI Layer 1 protocol, has officially entered its final Bonus Round after completing all 15 presale stages and securing over $21 million in early contributions. Priced at a fixed $0.007125, the Bonus Round gives developers and early supporters one last opportunity to acquire LCAI tokens before the upcoming mainnet launch in July.

SHREWSBURY, United Kingdom, July 06, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a next-generation Layer 1 blockchain platform purpose-built for decentralized artificial intelligence, has officially launched its Bonus Round after completing all 15 presale stages and raising more than $21 million in early contributions. This new phase offers fixed pricing at $0.007125 and is the final opportunity for supporters to gain early access ahead of the project’s mainnet launch, scheduled for July 2025.

SHREWSBURY, United Kingdom, July 06, 2025 (GLOBE NEWSWIRE) -- Lightchain AI a decentralized platform at the intersection of blockchain and artificial intelligence, today announced the launch of its Bonus Round following the successful completion of all 15 presale stages. The project has now raised $21 million, securing strong early participation ahead of its mainnet launch scheduled for July 2025.

SHREWSBURY, United Kingdom, July 06, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, a next-generation decentralized AI infrastructure project, has officially entered its Final Bonus Round, following the successful completion of all 15 presale stages and raising $20.9 million in token sales. This milestone reflects strong market confidence and positions the project ahead of its anticipated mainnet launch in July 2025.

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of $1.12, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.